Amber Denham

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Response-Adapted Ultralow-Dose Therapy Demonstrates Beneficial Outcomes for Patients With Indolent Orbital B-Cell Lymphoma

07/31/2024

Amber Denham ;

Response-adapted ultralow-dose therapy for patients with indolent orbital B-cell lymphoma demonstrated reduced radiation exposure, insignificant toxic effects, and superior disease outcomes, according to results from a phase 2 trial.

Response-adapted ultralow-dose...

07/31/2024

Oncology

News

Potential for Shorter Monitoring Period for Patients With R/R MM Following CAR-T Therapy

07/26/2024

Amber Denham ;

A shorter monitoring period may be reasonable for patients with relapsed/refractory multiple myeloma who underwent CAR-T therapy following results that suggest a low risk of cytokine release syndrome and immune effector cell-associated...

A shorter monitoring period may...

07/26/2024

Oncology

News

Utilizing T-Cell Assays in Diagnosing Familial Hemophagocytic Lymphohistiocytosis and Defects in Lymphocyte Exocytosis

07/25/2024

Amber Denham ;

According to a prospective analysis, a combined use of TCR-triggered T-cell and FcR-triggered NK-cell exocytosis assays demonstrated efficacy in diagnosing familial hemophagocytic lymphohistiocytosis and defects in lymphocyte exocytosis.

According to a prospective...

07/25/2024

Oncology

News

Brentuximab Vedotin and Ibrutinib Combination Fails to Provide Safety Among Patients With R/R Hodgkin Lymphoma

07/23/2024

Amber Denham ;

According to results from a phase 2 trial, brentuximab vedotin and ibrutinib therapy demonstrated activity among patients with R/R Hodgkin lymphoma, however the combination cannot be recommended for future therapeutic development due to...

According to results from a...

07/23/2024

Oncology

News

Weekly Carfilzomib, Pomalidomide, and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

07/09/2024

Amber Denham ;

Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.

Phase 2 results from the SELECT...

07/09/2024

Oncology

News

Post-Transplantation Cyclophosphamide vs ATG for GVHD Prophylaxis Among Patients Undergoing Allogeneic Stem Cell Transplant From Mismatched Unrelated Donors

07/02/2024

Amber Denham ;

A retrospective analysis demonstrated that post-transplantation cyclophosphamide yielded survival and non-relapse mortality benefit compared to anti-thymocyte globulin treatment for GVHD prophylaxis among patients undergoing allogeneic stem...

A retrospective analysis...

07/02/2024

Oncology